🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06699420
Recruiting Phase 4

Qishenyiqi Dripping Pill for Coronary Microvascular Disease

NCT06699420 · tracked via the Priya Life Science China tracker
Sponsor
Qilu Hospital of Shandong University
Phase
Phase 4
Started
2023-11-08
Last updated
2024-11-21

Condition(s) studied

Coronary Microvascular Disease

Investigational drug(s) / intervention(s)

Qishenyiqi dripping pills 1 bag, three times a dayPlacebo 1 bag, three times a day

Qishenyiqi dripping pills 1 bag, three times a day: Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months

Placebo 1 bag, three times a day: Placebo, 1 bag once, three times a day, 12 months

Study summary

To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

Eligibility

Sex
ALL
Min age
40 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks; * Coronary normal or stenosis \< 20%; * Ischemic depression in ST segment during resting or exercise; * Blood flow reserve (CFR) of the anterior descending coronary artery \< 2.0; * Subjects or their guardians agreed to participate in this study. Exclusion Criteria: * Previous myocardial infarction or PCI or CABG treatment; * A history of heart failure; * Severe arrhythmia; * Refractory hypertension or hypertension accompanied by left ventricular wall thickness \> 12 mm; * Familial hypercholesterolemia; * Takayasu arteritis, Kawasaki disease or coronary artery malformation; * Pregnant or nursing, or having the intention to give birth within one year; * Hepatic or renal dysfunction; * Allergic to contrast agents or traditional Chinese medicines; * Patients who participated in clinical research of other drugs within 3 months before being selected.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Qianfoshan Hospital, Shandong University Jinan Shandong Active Not Recruiting
Qilu Hospital of Shandong University Jinan Shandong Recruiting
Jinan Central Hospital Affiliated to Shandong First Medical University Jinan Shandong Recruiting

More Qilu Hospital of Shandong University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06699420 on ClinicalTrials.gov ↗ ← All trials in China